Clinical Pharmacology of Malaria Control and Elimination: Pharmacodynamics ofArtemisinin-based Combination Agents and their Barriers to Drug Resistance

控制和消除疟疾的临床药理学:青蒿素类复方药物的药效学及其耐药性障碍

基本信息

  • 批准号:
    10549359
  • 负责人:
  • 金额:
    $ 19.01万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-02-13 至 2025-01-31
  • 项目状态:
    未结题

项目摘要

Project Summary/Abstract Background. The proposed mentored research program is an investigation of chemotherapeutics for malaria elimination led by Dr. Matthew Ippolito under the mentorship of Dr. Theresa Shapiro, an expert in antiparasitic pharmacology, and others. The project will join clinical pharmacology analytics with molecular and genetic approaches to establish the pharmacokinetics (PK, drug exposure) and pharmacodynamics (PD, drug effect) of first-line antimalarial agents for gametocyte clearance and protection against reinfection, and characterize their relative barriers to drug resistance. Dr. Ippolito will acquire expertise in advanced PK/PD methods and clinical trial conduct. At the end of the award period, he will be prepared to pursue a career as an independent investigator with a focus on field-based clinical pharmacology studies of antimalarial drugs both extant and novel. Candidate. Dr. Ippolito is a board-certified internist, infectious disease specialist, and clinical pharmacologist at the Johns Hopkins University School of Medicine, and PhD candidate in the Johns Hopkins University Graduate Training Program in Clinical Investigation with a background in malaria-related research. Research. The proposed research will leverage existing and forthcoming clinical trial specimens from study participants treated for uncomplicated malaria with one of two antimalarial drug combinations, artemether- lumefantrine or dihydroartemisinin-piperaquine. Specimens will be processed to generate PK data (drug concentration) and PD data (parasitological outcomes, drug resistance genotypes). PK and PD variables will be analyzed using compartmental and nonlinear mixed effects models. Environment and Funding. The research activities will be carried out at Johns Hopkins University and collaborators' institutions. The antiparasitic laboratories of the primary mentor, Theresa Shapiro, MD, PhD— former director of the Johns Hopkins Division of Clinical Pharmacology and previous head of its Clinical Pharmacology Analytical Laboratory—contain the requisite instrumentation for liquid chromatography-mass spectrometry PK analyses; and the laboratories of the Johns Hopkins Malaria Research Institute and its partners have state-of-the-art instruments for molecular diagnostics and genetic sequencing of malaria parasites. Relevance to Public Health. Malaria remains a major public health issue, with nearly a half-million deaths each year arising from over 200 million infections. Absent a sufficiently effective vaccine, antimalarial drugs remain a vital component of malaria control programs. Their incompletely characterized PK/PD profiles and unknown barriers to resistance translate to opportunities for further research to inform drug optimization. The proposed training plan and analytic approaches also have potential applications to new antimalarial agents as they emerge from the drug development pipeline.
项目总结/摘要 背景建议的指导研究计划是一项疟疾化疗药物的调查 在抗寄生虫专家Theresa Shapiro博士的指导下,由Matthew Ippolito博士领导的消除 药理学和其他。该项目将把临床药理学分析与分子和遗传学分析结合起来, 确定药代动力学(PK,药物暴露)和药效学(PD,药物效应)的方法 用于配子体清除和防止再感染的一线抗疟药, 它们对耐药性的相对屏障。Ippolito博士将获得先进PK/PD方法的专业知识, 临床试验实施。在奖励期结束时,他将准备以独立人士的身份从事职业生涯。 研究人员,重点是对现有抗疟药物和 小说 候选人Ippolito博士是一位委员会认证的内科医生,传染病专家和临床药理学家, 约翰霍普金斯大学医学院,约翰霍普金斯大学博士候选人 临床调查研究生培训计划,具有疟疾相关研究背景。 research.拟议的研究将利用来自研究的现有和即将进行的临床试验样本 参与者接受了两种抗疟药物组合之一的无并发症疟疾治疗, 苯芴醇或双氢青蒿素-哌喹。将处理标本以生成PK数据(药物 浓度)和PD数据(寄生虫学结果,耐药基因型)。PK和PD变量将 使用房室和非线性混合效应模型进行分析。 环境和资金。研究活动将在约翰霍普金斯大学进行, 合作机构。主要导师Theresa Shapiro,MD,PhD的抗寄生虫实验室- 约翰霍普金斯临床药理学部前主任, 药理学分析实验室-包含液相色谱-质谱所需的仪器 以及约翰霍普金斯疟疾研究所的实验室及其 合作伙伴拥有最先进的疟疾分子诊断和基因测序仪器 寄生虫 与公共卫生相关。疟疾仍然是一个主要的公共卫生问题,有近50万人死亡 每年有超过2亿的感染病例。缺乏足够有效的疫苗、抗疟药物 仍然是疟疾控制方案的重要组成部分。其PK/PD特征不完全, 未知的耐药性障碍转化为进一步研究的机会,以告知药物优化。的 拟议的培训计划和分析方法也有可能应用于新的抗疟剂, 它们来自于药物开发管道。

项目成果

期刊论文数量(9)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Reducing misclassification bias in severe malaria research.
  • DOI:
    10.1016/j.xcrm.2022.100789
  • 发表时间:
    2022-10-18
  • 期刊:
  • 影响因子:
    14.3
  • 作者:
    Ippolito, Matthew M.;Robinson, Matthew L.
  • 通讯作者:
    Robinson, Matthew L.
House Structure Is Associated with Malaria among Febrile Patients in a High-Transmission Region of Zambia.
赞比亚高传播地区的发热患者中,房屋结构与疟疾有关。
  • DOI:
    10.4269/ajtmh.20-1378
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Sikalima,Jay;Schue,JessicaL;Hill,SarahE;Mulenga,Modest;Handema,Ray;Daka,Victor;Chileshe,Justin;Kasongo,Webster;Chaponda,Mike;BukasaKabuya,Jean-Bertin;Moss,WilliamJ;Ippolito,MatthewM;SouthernandCentralAfricaInternationalCe
  • 通讯作者:
    SouthernandCentralAfricaInternationalCe
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Matthew Michael Ippolito其他文献

Matthew Michael Ippolito的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Matthew Michael Ippolito', 18)}}的其他基金

The Averting Readmissions for Malaria and Outpatient Reinfections (ARMOR) Trial
避免疟疾和门诊再感染再入院 (ARMOR) 试验
  • 批准号:
    10328316
  • 财政年份:
    2022
  • 资助金额:
    $ 19.01万
  • 项目类别:
Clinical Pharmacology of Malaria Control and Elimination: Pharmacodynamics ofArtemisinin-based Combination Agents and their Barriers to Drug Resistance
控制和消除疟疾的临床药理学:青蒿素类复方药物的药效学及其耐药性障碍
  • 批准号:
    9891336
  • 财政年份:
    2020
  • 资助金额:
    $ 19.01万
  • 项目类别:
Clinical Pharmacology of Malaria Control and Elimination: Pharmacodynamics ofArtemisinin-based Combination Agents and their Barriers to Drug Resistance
控制和消除疟疾的临床药理学:青蒿素类复方药物的药效学及其耐药性障碍
  • 批准号:
    10333361
  • 财政年份:
    2020
  • 资助金额:
    $ 19.01万
  • 项目类别:

相似海外基金

Life outside institutions: histories of mental health aftercare 1900 - 1960
机构外的生活:1900 - 1960 年心理健康善后护理的历史
  • 批准号:
    DP240100640
  • 财政年份:
    2024
  • 资助金额:
    $ 19.01万
  • 项目类别:
    Discovery Projects
Development of a program to promote psychological independence support in the aftercare of children's homes
制定一项计划,促进儿童之家善后护理中的心理独立支持
  • 批准号:
    23K01889
  • 财政年份:
    2023
  • 资助金额:
    $ 19.01万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Integrating Smoking Cessation in Tattoo Aftercare
将戒烟融入纹身后护理中
  • 批准号:
    10452217
  • 财政年份:
    2022
  • 资助金额:
    $ 19.01万
  • 项目类别:
Integrating Smoking Cessation in Tattoo Aftercare
将戒烟融入纹身后护理中
  • 批准号:
    10670838
  • 财政年份:
    2022
  • 资助金额:
    $ 19.01万
  • 项目类别:
Aftercare for young people: A sociological study of resource opportunities
年轻人的善后护理:资源机会的社会学研究
  • 批准号:
    DP200100492
  • 财政年份:
    2020
  • 资助金额:
    $ 19.01万
  • 项目类别:
    Discovery Projects
Creating a National Aftercare Strategy for Survivors of Pediatric Cancer
为小儿癌症幸存者制定国家善后护理策略
  • 批准号:
    407264
  • 财政年份:
    2019
  • 资助金额:
    $ 19.01万
  • 项目类别:
    Operating Grants
Aftercare of green infrastructure: creating algorithm for resolving human-bird conflicts
绿色基础设施的善后工作:创建解决人鸟冲突的算法
  • 批准号:
    18K18240
  • 财政年份:
    2018
  • 资助金额:
    $ 19.01万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of an aftercare model for children who have experienced invasive procedures
为经历过侵入性手术的儿童开发善后护理模型
  • 批准号:
    17K12379
  • 财政年份:
    2017
  • 资助金额:
    $ 19.01万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of a Comprehensive Aftercare Program for children's self-reliance support facility
为儿童自力更生支持设施制定综合善后护理计划
  • 批准号:
    17K13937
  • 财政年份:
    2017
  • 资助金额:
    $ 19.01万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Project#2 Extending Treatment Effects Through an Adaptive Aftercare Intervention
项目
  • 批准号:
    8742767
  • 财政年份:
    2014
  • 资助金额:
    $ 19.01万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了